title: Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.
abstract: Human anti-V3 monoclonal antibodies (mAbs) generated from HIV-1 infected individuals display diversity in the range of their cross-neutralization that may be related to their immunogenetic background. The study of the immunoglobulin (Ig) variable region gene usage of heavy chains have shown a preferential usage of the VH5-51 gene segment which was detected in 35% of 51 human anti-V3 mAbs. In contrast, human mAbs against other envelope regions of HIV-1 (anti-Env), including the CD4-binding domain, the CD4-induced epitope, and gp41 preferentially used the VH1-69 gene segment, and none of them used the VH5-51 gene. Furthermore, the usage of the VH4 family by anti-V3 mAbs was restricted to only one gene segment, VH4-59, while the VH3 gene family was used at a significantly lower frequency by all of the analyzed anti-HIV-1 mAbs. Multivariate analysis showed that usage of VH gene segments was significantly different between anti-V3 and anti-Env mAbs, and compared to antibodies from healthy subjects. In addition, the anti-V3 mAbs preferentially used the JH3 and D2-15 gene segments. The preferential usage of selected Ig gene segments and the characteristic pattern of Ig gene usage by anti-V3 mAbs can be related to the conserved structure of the V3 region.
authors.affiliation: Department of Pathology, New York University School of Medicine, New York, NY 10016, USA. mirek@gorny@med.nyu.edu
authors.forename: Miroslaw K
authors.initials: MK
authors.lastname: Gorny
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Wang
authors.forename: Constance
authors.initials: C
authors.lastname: Williams
authors.forename: Barbara
authors.initials: B
authors.lastname: Volsky
authors.forename: Kathy
authors.initials: K
authors.lastname: Revesz
authors.forename: Bradley
authors.initials: B
authors.lastname: Witover
authors.forename: Sherri
authors.initials: S
authors.lastname: Burda
authors.forename: Mateusz
authors.initials: M
authors.lastname: Urbanski
authors.forename: Phillipe
authors.initials: P
authors.lastname: Nyambi
authors.forename: Chavdar
authors.initials: C
authors.lastname: Krachmarov
authors.forename: Abraham
authors.initials: A
authors.lastname: Pinter
authors.forename: Susan
authors.initials: S
authors.lastname: Zolla-Pazner
authors.forename: Arthur
authors.initials: A
authors.lastname: Nadas
mesh_terms: D000911:Antibodies, Monoclonal / Q000235:genetics* / Q000276:immunology; D000914:Antibodies, Viral / Q000235:genetics* / Q000276:immunology; D000918:Antibody Specificity / Q000235:genetics* / Q000276:immunology; D000939:Epitopes / Q000235:genetics* / Q000276:immunology; D015700:HIV Envelope Protein gp41; D015658:HIV Infections / Q000235:genetics* / Q000276:immunology; D015497:HIV-1; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000939:Epitopes; D015700:HIV Envelope Protein gp41; D007135:Immunoglobulin Variable Region; C514787:gp41 protein, Human immunodeficiency virus 1